253 related articles for article (PubMed ID: 28292399)
1. Current and Future Medical Treatment of Obesity.
Umashanker D; Igel LI; Kumar RB; Aronne LJ
Gastrointest Endosc Clin N Am; 2017 Apr; 27(2):181-190. PubMed ID: 28292399
[TBL] [Abstract][Full Text] [Related]
2. Current pharmacotherapy for obesity.
Srivastava G; Apovian CM
Nat Rev Endocrinol; 2018 Jan; 14(1):12-24. PubMed ID: 29027993
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy for the management of obesity.
Patel D
Metabolism; 2015 Nov; 64(11):1376-85. PubMed ID: 26342499
[TBL] [Abstract][Full Text] [Related]
5. Medical management of obesity.
Giri M
Acta Clin Belg; 2006; 61(5):286-94. PubMed ID: 17240746
[TBL] [Abstract][Full Text] [Related]
6. Next generation of weight management medications: implications for diabetes and CVD risk.
Wharton S; Serodio KJ
Curr Cardiol Rep; 2015 May; 17(5):35. PubMed ID: 25894803
[TBL] [Abstract][Full Text] [Related]
7. Updates on obesity pharmacotherapy.
Velazquez A; Apovian CM
Ann N Y Acad Sci; 2018 Jan; 1411(1):106-119. PubMed ID: 29377198
[TBL] [Abstract][Full Text] [Related]
8. Interface between pharmacotherapy and genes in human obesity.
O'Connor A; Swick AG
Hum Hered; 2013; 75(2-4):116-26. PubMed ID: 24081227
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy of Obesity: Limits and Perspectives.
Rosa-Gonçalves P; Majerowicz D
Am J Cardiovasc Drugs; 2019 Aug; 19(4):349-364. PubMed ID: 30793263
[TBL] [Abstract][Full Text] [Related]
10. Recent concepts of pharmacotherapy and bariatric surgery for childhood obesity: an overview.
Gogakos A; Tzotzas TC; Krassas GE
Pediatr Endocrinol Rev; 2009 Dec; 7(2):3-14. PubMed ID: 20118889
[TBL] [Abstract][Full Text] [Related]
11. Drug treatment of obesity in cardiovascular disease.
Charakida M; Finer N
Am J Cardiovasc Drugs; 2012 Apr; 12(2):93-104. PubMed ID: 22292446
[TBL] [Abstract][Full Text] [Related]
12. Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk.
Caterson ID; Finer N
Asia Pac J Clin Nutr; 2006; 15 Suppl():55-62. PubMed ID: 16928662
[TBL] [Abstract][Full Text] [Related]
13. Cardiometabolic Effects of Anti-obesity Pharmacotherapy.
Crawford AR; Alamuddin N; Amaro A
Curr Atheroscler Rep; 2018 Mar; 20(4):18. PubMed ID: 29511882
[TBL] [Abstract][Full Text] [Related]
14. FDA-Approved Anti-Obesity Drugs in the United States.
Daneschvar HL; Aronson MD; Smetana GW
Am J Med; 2016 Aug; 129(8):879.e1-6. PubMed ID: 26949003
[TBL] [Abstract][Full Text] [Related]
15. The new role of pharmacotherapy for weight reduction in obesity.
Fernstrom MH; Fernstrom JD
Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
[TBL] [Abstract][Full Text] [Related]
16. Medication-Assisted Weight Loss in the Age of Obesity.
Leahy LG
J Psychosoc Nurs Ment Health Serv; 2017 Aug; 55(8):21-26. PubMed ID: 28771283
[TBL] [Abstract][Full Text] [Related]
17. Targeting thermogenesis and related pathways in anti-obesity drug discovery.
Clapham JC; Arch JR
Pharmacol Ther; 2011 Sep; 131(3):295-308. PubMed ID: 21514319
[TBL] [Abstract][Full Text] [Related]
18. Obesity: new perspectives and pharmacotherapies.
Palamara KL; Mogul HR; Peterson SJ; Frishman WH
Cardiol Rev; 2006; 14(5):238-58. PubMed ID: 16924165
[TBL] [Abstract][Full Text] [Related]
19. ASHP therapeutic position statement on the safe use of pharmacotherapy for obesity management in adults. Developed by the ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on April 23, 2001.
Am J Health Syst Pharm; 2001 Sep; 58(17):1645-55. PubMed ID: 11556659
[TBL] [Abstract][Full Text] [Related]
20. Progress and challenges in anti-obesity pharmacotherapy.
Bessesen DH; Van Gaal LF
Lancet Diabetes Endocrinol; 2018 Mar; 6(3):237-248. PubMed ID: 28919062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
